IDEAYA Biosciences IDYA 深 滬
等待開盤 03-26 09:30:00 美东时间
31.39
+0.860
+2.82%
華盛通- 最 高31.76
- 今 開30.89
- 成交量 85.43万股
- 最 低 30.84
- 昨 收 30.53
- 總市值 27.56亿
- 52周最高 39.28
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 13.45
- 委 比 -98.99%
- 總股本 8781.40万
- 歷史最高 47.735
- 量 比 0.62
- 振 幅 3.01%
- 歷史最低 2.95
- 每 手 1
- 風險率 6.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IDEAYA slips on delaying results from darovasertib uveal melanoma trial
IDEAYA Biosciences (IDYA) is down ~5% in Monday trading after announcing it is delaying the release of topline results from a phase 2/3 trial of darovasertib for first-line metastatic uveal melanoma, ...
03-23 22:53
IDEAYA forecasts OptimUM-02 trial database lock in April 2026
IDEAYA forecasts OptimUM-02 trial database lock in April 2026 IDEAYA said the Phase 2/3 OptimUM-02 trial of darovasertib in first-line HLA-A2-negative metastatic uveal melanoma is expected to reach database lock in the first half of April. Topline data analysis is expected to follow the database loc
03-22 22:12
IDEAYA Biosciences to present three posters at AACR Annual Meeting
IDEAYA Biosciences to present three posters at AACR Annual Meeting IDEAYA will present three posters at the AACR Annual Meeting in San Diego on April 19-21, 2026. One poster session is scheduled for April 19, 2026 from 2:00pm to 5:00pm PDT. Two poster sessions are scheduled for April 21, 2026 from 9
03-18 18:01
Ideaya Biosciences Enrolls The First Patient In Its Phase 1 Trial Of IDE892 for MTAP-Deleted Solid Tumors, Including Non-small Cell Lung Cancer And Pancreatic Cancer
Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency in MTAP-deleted cell linesIDE892 is being evaluated as a monotherapy
03-09 18:03
IDEAYA Biosciences reports first patient enrolled in Phase 1 IDE892 trial for MTAP-deleted solid tumors
IDEAYA Biosciences reports first patient enrolled in Phase 1 IDE892 trial for MTAP-deleted solid tumors IDEAYA reported first patient enrollment in a Phase 1 trial of IDE892, a PRMT5 inhibitor being evaluated as monotherapy for MTAP-deleted solid tumors including NSCLC and pancreatic cancer. IDE892
03-09 18:02
IDEAYA Biosciences Director Jeffrey Stein Acquires Common Shares
IDEAYA Biosciences Director Jeffrey Stein Acquires Common Shares Jeffrey Stein, a director of IDEAYA Biosciences Inc., reported acquiring 50,000 shares of the company’s common stock. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologie
03-03 08:18
百奥赛图-B午前涨超6% IDE034首例患者给药触发500万美元里程碑款项
百奥赛图-B（02315）午前涨超6%，截至发稿，股价上涨6.49%，现报53.35港元，成交额2847.94万港元。 IDEAYA宣布，其在研PTK7/...
02-26 11:51
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034 Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161 B7H3/PTK7 co-expressed ...
02-25 19:00
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theo...
02-23 19:00
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
